Drugs / Indapamide
Indapamide
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | LOZOL | — | 1993-04-29 | fda.gov ↗ |
| Approved | US (FDA) | LOZOL | — | 1983-07-06 | fda.gov ↗ |
Trials 31
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06012487 | May → Dec 2026 expected | — | Cedars-Sinai Medical Center | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05097794 | Aug → Oct 2021 | hypertensive disorder | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT06212648 | Mar → Nov 2022 | essential hypertension | Shin Poong Pharmaceutical Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT05013463 | Oct 2021 → Sep 2023 | secondary progressive multiple sclerosis | University of Calgary | Unknown | No outcome recorded |
| Phase 2 | NCT03640312 | Aug 2019 → May 2022 | hypertensive disorder | Washington University School of Medicine | Completed | Missed primary |
| Phase 310 trials · 4 met primary | ||||||
| Phase 3 | NCT05878561 | Nov 2022 → Dec 2024 | essential hypertension | Boryung Pharmaceutical Co., Ltd | Completed | Met primary |
| Phase 3 | NCT05110898 | Aug 2022 → Aug 2023 | essential hypertension | Brainfarma | Unknown | No outcome recorded |
| Phase 3 | NCT06500689 | Dec 2021 → Nov 2023 | essential hypertension | Shenzhen Salubris Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04518293 | Jul 2021 → Aug 2023 | hypertensive disorder | George Medicines PTY Limited | Completed | Met primary |
| Phase 3 | NCT04518306 | Jun 2021 → Sep 2023 | hypertensive disorder | George Medicines PTY Limited | Completed | Met primary |
| Phase 3 | NCT04686643 | Feb 2021 → Feb 2022 | hypertensive disorder | Ahn-Gook Pharmaceuticals Co.,Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT03785067 | Feb 2020 → Feb 2021 | hypertensive disorder, intracerebral hemorrhage, vascular dementia | The George Institute | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01620788 | Nov 2019 → Jul 2023 | hypertensive disorder | EMS | Suspended | No outcome recorded |
| Phase 3 | NCT05820880 | May 2019 → Feb 2022 | essential hypertension | Servier | Completed | No outcome recorded |
| Phase 3 | NCT02699645 | Sep 2017 → Aug 2025 | hypertensive disorder, intracerebral hemorrhage | The George Institute | Completed | Met primary |
| Phase 412 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT07240909 | Jan → Dec 2026 expected | hypertensive disorder | The Third Xiangya Hospital of Central South University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06275763 | Oct 2023 → Dec 2025 | hypertensive disorder | National Institute of Cardiology, Warsaw, Poland | Unknown | No outcome recorded |
| Phase 4 | NCT05683301 | Aug 2022 → Aug 2024 | essential hypertension | Centre for Chronic Disease Control, India | Completed | No outcome recorded |
| Phase 4 | NCT05377203 | Jul 2022 → Jul 2023 | hypertensive disorder | The Third Xiangya Hospital of Central South University | Completed | Met primary |
| Phase 4 | NCT04330300 | Apr 2020 → Jul 2021 | COVID-19, essential hypertension | National University of Ireland, Galway, Ireland | Suspended | No outcome recorded Stop: Business |
| Phase 4 | NCT03738761 | Feb 2018 → Sep 2019 | essential hypertension | KRKA | Completed | No outcome recorded |
| Phase 4 | NCT03319823 | Oct 2017 → Feb 2019 | hypertensive disorder | Cedars-Sinai Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT01172431 | Sep 2010 → Mar 2012 | hypertensive disorder, impaired renal function disease | West China Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00980187 | Mar 2008 → Aug 2010 | hypertensive disorder, type 2 diabetes mellitus | LaborMed Pharma S.A. | Completed | No outcome recorded |
| Phase 4 | NCT00128518 | Oct 2004 → Sep 2010 | hypertensive disorder | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 4 | NCT00122811 | Nov 2000 → Oct 2008 | hypertensive disorder | Imperial College London | Unknown | Missed primary |
| Phase not applicable4 trials | ||||||
| — | NCT07679828 | Jul 2026 → Dec 2029 expected | hyperlipidemia, hypertensive disorder, type 2 diabetes mellitus | China Medical University, China | Recruiting | No outcome recorded |
| — | NCT07259733 | Jul 2023 → Dec 2026 expected | resistant hypertension | Instituto Dante Pazzanese de Cardiologia | Recruiting | No outcome recorded |
| — | NCT03783754 | Aug 2018 → Mar 2021 | hypertensive disorder, intracerebral hemorrhage, vascular dementia | The George Institute | Terminated | No outcome recorded |
| — | NCT07652567 | Jan 2007 → Apr 2026 | hypertensive disorder | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Comparator or background therapy26 trials | ||||||
| Phase 1 | NCT07421414 Comparator | Apr → Jun 2026 overdue | essential hypertension | Boryung Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07064525 Comparator | Dec 2024 → Dec 2025 overdue | advanced heart failure, diabetes mellitus, essential hypertension, moderate heart failure | Shin Poong Pharmaceutical Co. Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06111885 Comparator | Oct 2024 → Jun 2027 expected | urolithiasis | Insel Gruppe AG, University Hospital Bern | Recruiting | No outcome recorded |
| Phase 2 | NCT05103332 Background | Nov 2021 → Dec 2023 | essential hypertension | Alnylam Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03246555 Comparator | Jul 2016 → Aug 2019 | — | Boryung Pharmaceutical Co., Ltd | Completed | Met primary |
| Phase 3 | NCT00145925 Comparator | Jun 2001 → Mar 2008 | type 2 diabetes mellitus | The George Institute | Completed | Mixed |
| Phase 4 | NCT07034677 Comparator | Aug → Dec 2025 overdue | hypoparathyroidism | Lars Rejnmark | Recruiting | No outcome recorded |
| Phase 4 | NCT05365477 Comparator | Aug 2022 → Sep 2025 | nephrolithiasis | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT05294484 Comparator | Mar → Jul 2022 | — | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT05169021 Comparator | Dec 2021 → Dec 2024 overdue | stroke disorder | Beijing Tiantan Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04455178 Comparator | Sep 2020 → Dec 2023 | essential hypertension | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT03476616 Background | Sep 2018 → Jun 2025 | essential hypertension, obesity disorder | Hippocration General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT03747978 Comparator | Oct 2016 → May 2017 | hypertensive disorder, type 2 diabetes mellitus | Yaounde Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02710539 Comparator | Apr 2016 → Mar 2019 | hypertensive disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT02710552 Comparator | Apr 2016 → Mar 2019 | hypertensive disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 4 | NCT01588795 Comparator | Apr 2012 → Jan 2016 | diabetic kidney disease, proteinuria | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 4 | NCT01500590 Comparator | Nov 2011 → Aug 2018 | hypertensive disorder, type 2 diabetes mellitus | Hospital Authority, Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT00295542 Comparator | Mar 2000 → Apr 2009 | hypertensive disorder | University of Vigo | Completed | No outcome recorded |
| — | NCT04040634 Background | Aug 2019 → May 2026 overdue | cognitive disorder, diabetes mellitus, hypertensive disorder | Hospital Israelita Albert Einstein | Active not recruiting | No outcome recorded |
| — | NCT04036409 Background | Aug 2019 → May 2026 overdue | cognitive disorder, hypertensive disorder, ischemic stroke | Hospital Israelita Albert Einstein | Active not recruiting | No outcome recorded |
| — | NCT03626506 Comparator | Feb 2019 → Aug 2020 | hypertensive disorder | Peking University Third Hospital | Unknown | No outcome recorded |
| — | NCT02364089 Comparator | Apr 2015 → Mar 2022 | adrenal gland disorder | University Hospital, Bordeaux | Completed | No outcome recorded |
| — | NCT01996085 Comparator | Jan 2013 → Jun 2016 | hypertensive disorder | Military Institute od Medicine National Research Institute | Completed | No outcome recorded |
| — | NCT00691314 Comparator | Jun 2008 → Sep 2010 | atherosclerosis, transient ischemic attack | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00664846 Background | Apr 2008 → Dec 2010 | ischemic stroke | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 59 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | indapamide | “The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged,...” NCT04040634 ↗56“Replacement of ineffective antihypertensive treatment based on 3 or more antihypertensive drugs (single or dual drug preparations) with a triple single pill combination (SPC)...” NCT06275763 ↗ “Following a two-week placebo run-in period, 253 patients of SPC1001 were randomized into the High, Mid1, Mid2, and Low groups, which consisted of a fixed-dose triple...” PMID 41162308 ↗ Oct 2025 “Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the...” NCT01588795 ↗ “amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily” NCT01500590 ↗ “Participants received either a quadpill of candesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg or candesartan 8 mg for 12 weeks.” PMID 38584159 ↗ Apr 2024 “preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine +amlodipine” NCT04036409 ↗ “These formulations include olmesartan medoxomil/amlodipine, rosuvastatin, ezetimibe, and dapagliflozin, with indapamide included in selected formulations.” NCT07679828 ↗ “Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone” NCT00684489 ↗ “Hydrochlorothiazide, metolazone, chlorthalidone, chlorothiazide, bendroflumethiazide, indapamide” NCT04330300 ↗ “fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide” NCT07064525 ↗ |
| Known as | IND | “This study evaluated the efficacy and safety of fimasartan (FMS) and indapamide (IND) sustained release (SR) combination therapy.” PMID 42163997 ↗ May 2026 |
| Known as | Indapamide Tablets | “Hypervolemic type: Indapamide Tablets 2.5mg, once daily, orally.” NCT07240909 ↗ |
| Known as | Natrilix | “Initially, the participant will be treated with Benicar® (olmesartan) 20mg and Natrilix® (indapamide) 1,5 mg.” NCT05110898 ↗ |
| Modality | Small molecule | “a thiazide-like diuretic (indapamide 1.5 mg SR)” PMID 20573778 ↗ Jun 2010 |
| Route | Oral | “1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months” NCT00980187 ↗ |